GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025.
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Seeking Alpha / 2 hours ago 1 Views
Comments